These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 21638754)

  • 1. Juvenile animal studies and pediatric drug development: a European regulatory perspective.
    Carleer J; Karres J
    Birth Defects Res B Dev Reprod Toxicol; 2011 Aug; 92(4):254-60. PubMed ID: 21638754
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Juvenile animal studies in the development of pediatric medicines: experience from European medicines and pediatric investigation plans.
    Duarte DM; Silva-Lima B
    Birth Defects Res B Dev Reprod Toxicol; 2011 Aug; 92(4):353-8. PubMed ID: 21594973
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Juvenile animal studies and pediatric drug development retrospective review: use in regulatory decisions and labeling.
    Tassinari MS; Benson K; Elayan I; Espandiari P; Davis-Bruno K
    Birth Defects Res B Dev Reprod Toxicol; 2011 Aug; 92(4):261-5. PubMed ID: 21594977
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The value of juvenile animal studies: a Japanese industry perspective.
    Shimomura K
    Birth Defects Res B Dev Reprod Toxicol; 2011 Aug; 92(4):266-8. PubMed ID: 21594974
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The value of juvenile animal studies "What have we learned from preclinical juvenile toxicity studies? II".
    Bailey GP; Mariën D
    Birth Defects Res B Dev Reprod Toxicol; 2011 Aug; 92(4):273-91. PubMed ID: 22623019
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The value of juvenile animal studies: a pediatric clinical perspective.
    Rose K
    Birth Defects Res B Dev Reprod Toxicol; 2011 Aug; 92(4):252-3. PubMed ID: 21594978
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nonclinical support of pediatric drug development in a global context: an industry perspective.
    Cappon GD
    Birth Defects Res B Dev Reprod Toxicol; 2011 Aug; 92(4):269-72. PubMed ID: 21594976
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preclinical safety evaluations supporting pediatric drug development with biopharmaceuticals: strategy, challenges, current practices.
    Morford LL; Bowman CJ; Blanset DL; Bøgh IB; Chellman GJ; Halpern WG; Weinbauer GF; Coogan TP
    Birth Defects Res B Dev Reprod Toxicol; 2011 Aug; 92(4):359-80. PubMed ID: 21770023
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Juvenile animal studies for the development of paediatric medicines: a description and conclusions from a European Medicines Agency workshop on juvenile animal testing for nonclinical assessors.
    Silva-Lima B; Due Theilade-Thomsen M; Carleer J; Vidal JM; Tomasi P; Saint-Raymond A
    Birth Defects Res B Dev Reprod Toxicol; 2010 Dec; 89(6):467-73. PubMed ID: 20632393
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Value of juvenile animal studies.
    Leconte I; Bailey G; Davis-Bruno K; Hew KW; Kim J; Silva Lima B; Liminga U; Moffit J; De Schaepdrijver L; Schmitt G; Tassinari M; Thompson K; Hurtt M
    Birth Defects Res B Dev Reprod Toxicol; 2011 Aug; 92(4):292-303. PubMed ID: 22623020
    [TBL] [Abstract][Full Text] [Related]  

  • 11. European Union pediatric legislation jeopardizes worldwide, timely future advances in the care of children with cancer.
    Rose K
    Clin Ther; 2014 Feb; 36(2):163-77. PubMed ID: 24529288
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Juvenile animal toxicity study designs to support pediatric drug development.
    Cappon GD; Bailey GP; Buschmann J; Feuston MH; Fisher JE; Hew KW; Hoberman AM; Ooshima Y; Stump DG; Hurtt ME
    Birth Defects Res B Dev Reprod Toxicol; 2009 Dec; 86(6):463-9. PubMed ID: 20025047
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An update of juvenile animal studies in the European Union: What do the numbers say?
    Hurtt ME; Engel S
    Reprod Toxicol; 2015 Aug; 56():105-8. PubMed ID: 25937597
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Three years of paediatric regulation in the European Union.
    Olski TM; Lampus SF; Gherarducci G; Saint Raymond A
    Eur J Clin Pharmacol; 2011 Mar; 67(3):245-52. PubMed ID: 21286912
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of modeling and simulation in pediatric investigation plans.
    Manolis E; Osman TE; Herold R; Koenig F; Tomasi P; Vamvakas S; Saint Raymond A
    Paediatr Anaesth; 2011 Mar; 21(3):214-21. PubMed ID: 21244569
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and nutritional assessment of GM plants and derived food and feed: the role of animal feeding trials.
    EFSA GMO Panel Working Group on Animal Feeding Trials
    Food Chem Toxicol; 2008 Mar; 46 Suppl 1():S2-70. PubMed ID: 18328408
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The European Regulation on medicines for paediatric use.
    Dunne J
    Paediatr Respir Rev; 2007 Jun; 8(2):177-83. PubMed ID: 17574163
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Juvenile Animal Testing: Assessing Need and Use in the Drug Product Label.
    Baldrick P
    Ther Innov Regul Sci; 2018 Sep; 52(5):641-648. PubMed ID: 29714556
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The need for juvenile animal studies--a critical review.
    Soellner L; Olejniczak K
    Regul Toxicol Pharmacol; 2013 Feb; 65(1):87-99. PubMed ID: 23108189
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Real life juvenile toxicity case studies: the good, the bad and the ugly.
    De Schaepdrijver L; Rouan MC; Raoof A; Bailey GP; De Zwart L; Monbaliu J; Coogan TP; Lammens L; Coussement W
    Reprod Toxicol; 2008 Sep; 26(1):54-5. PubMed ID: 18514481
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.